PALO ALTO, Calif., July 8, 2004 (PRIMEZONE) -- Human BioSystems (OTCBB:HBSC) announced today it has entered into a contractual agreement with Waterville Investment Research of New York, to profile the company with an extensive research report for the investment community.
Human BioSystems (HBS) is a biomedical company focused on the creation of solutions and systems to extend the preservation period of biological materials such as blood platelets, the congealing component of blood, and donor organs including hearts, livers, kidneys, lungs and pancreas.
"We have commenced an intensive program to publicize our company and our exciting technologies and products both domestically and internationally and establish our position as the leader in our field," Harry Masuda, HBS President and CEO said. "Waterville Investment Research will play an integral role in this program."
Waterville Investment Research provides fundamental Wall Street investment research for Small-Cap companies. Forbes Magazine acknowledged the Waterville Philosophy in an article published in November 2003 on Independent Research. Waterville is looking for clients that have an expectation and appreciation for long-term consistency of reporting, results and news. Waterville was started in October of 2002 when the Dow was at 7500, Nasdaq was at 1200 and the Russell 2000 was at 340; thus, the bottom of the market.
"The belief was that after three down years, it was a good time to jump back into the Small-Cap market. Wall Street is typically very severe in its reaction to small companies in down markets, so the focus at Waterville is exclusively on Small-Cap stocks which Wall Street has ignored, abused and/or forgotten," said Mike Sweeney of Waterville Investment Research.
When Partners Bill Hayde and Mike Sweeney started the firm, they took a long-term view of the market and set up a five-year plan for Waterville and its client companies. In an era where there is great mistrust toward Corporate America, Wall Street and Small Cap Stocks, Waterville is taking the long-term view of the market. Good companies with good management and good products and services will ultimately outperform the market.
"HBS certainly meets our criteria with their management team and their cutting-edge technology," Mike Sweeney, Waterville Partner stated. "We look forward to a long and very successful relationship with them."
Human BioSystems is headquartered in Palo Alto, California.
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from future research and testing, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the technology we have acquired, failure of any such products to compete effectively with existing products, failure to develop a cost-effective commercial manufacturing method, the ability of the Company to fund additional studies and product development and other factors discussed in filings made by the Company with the Securities and Exchange Commission.